PP
SGMT icon

Paloma Partners’s Sagimet Biosciences SGMT Stock Holding History

Paloma Partners’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-26,700
Closed -$91.3K – 1623
2024
Q2 		$91.3K Buy
+26,700
New +$122K ﹤0.01% 1088

Other funds holding SGMT

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Paloma Partners's SGMT Position: Q3 2024 in Review

Paloma Partners sold out of Sagimet Biosciences (SGMT) in Q3 2024, closing a stake of 26,700 shares — an estimated $91.3K sold.

Paloma Partners first reported a position in SGMT in Q2 2024 and held it in 1 quarter. The position peaked at $91.3K in Q2 2024. 63 funds tracked by Wall St. Rank hold SGMT as of Q3 2024.

  • Paloma Partners reported no remaining Sagimet Biosciences position as of Q3 2024 after selling out during the quarter.
  • Paloma Partners sold 26,700 Sagimet Biosciences shares in Q3 2024, an estimated $91.3K.
  • Paloma Partners first reported a position in Sagimet Biosciences in Q2 2024 and held it in 1 quarter.
  • Paloma Partners's Sagimet Biosciences position peaked at $91.3K in Q2 2024.
  • 63 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q3 2024.

Based on Paloma Partners's 13F filing for Q3 2024, filed 14 Nov 2024.